Life Sciences
Top stories summarized by our editors
9/20/2019

AveXis, a Novartis unit, unveiled updated data from its late-stage trial assessing its gene therapy candidate Zolgensma, or onasemnogene abeparvovec-xioi, as a treatment for spinal muscular atrophy type 1. Data, which indicated the drug resulted in sustained benefit among participants in this patient group, were presented during the European Neurology Society Congress.

Full Story:
Seeking Alpha
9/20/2019

Bluebird Bio recently reported updated results from its Phase II/III trial evaluating its Lenti-D gene therapy that the company will use to support the treatment's potential fast-track approval during a presentation made at the congress of the European Paediatric Neurology Society. The investigational gene therapy is indicated as a treatment for cerebral adrenoleukodystrophy.

Full Story:
PMLive (UK)
More Summaries:
Bluebird Bio
9/20/2019

Themis Biosciences of Austria gained a little over $44 million from a Series D funding round to finance its late-stage trial evaluating its vaccine for chikungunya infections. The international trial will be conducted in the US and Europe and is slated to be launched in the coming months.

Full Story:
Labiotech (Germany)
9/20/2019

University of Cambridge investigators in the UK discovered that the tomato's Rider retrotransposons, also referred to as jumping genes, may prove useful in crop breeding to boost drought resistance not only in tomatoes but in crops where the jumping genes are also active, such as beetroot, quinoa and rapeseed, according to findings published in the journal PLOS Genetics. Global warming's extreme effects are damaging crops globally, and improving crop resilience is key to combating the challenges caused by climate change.

More Summaries:
University of Cambridge
9/20/2019

A Series E funding round raised $290 million for Ginkgo Bioworks, with the additional capital to support continued development of its cell programming platform. Gingko's synthetic biology technology is being used to create compounds from fermented yeast to be applied in the manufacture of products such as cosmetics, food ingredients, flavors, and fragrances.

Full Story:
Forbes
More Summaries:
Ginkgo BioWorks
9/20/2019

President Donald Trump is expected to meet with oil-state senators over the share of ethanol in the US fuel supply. Trump's visit last week with Midwestern senators raised the hopes of farmers and lawmakers that the Renewable Fuel Standard for 2020 would be increased by over 2 billion gallons from the current target proposed by the Environmental Protection Agency for next year.

Full Story:
Successful Farming
9/20/2019

Senate lawmakers have directed the CMS to boost Medicare reimbursement for non-opioid devices, a move the medical device industry also supports. In April, AdvaMed sent a letter to CMS Administrator Seema Verma, asking the agency to increase payments for non-opioid devices.

Full Story:
MedTech Dive
9/20/2019

BioStream has agreed to distribute IsoPlexis' IsoCode and IsoLight single-cell protein analysis products in Japan. The products provide highly multiplexed protein measurements at the single-cell level for use in development and biomarker discovery.

More Summaries:
BioStream, IsoPlexis
9/20/2019

A round of Series E financing has raised $290 million for Ginkgo Bioworks. Ginkgo plans to use the proceeds to expand its cell programming platform.

More Summaries:
Ginkgo BioWorks
9/20/2019

Novigenix has secured BioLizard's collaboration in developing an artificial intelligence-based algorithm to help transition its Colox immuno-transcriptomic RT-PCR early cancer detection platform onto the new LITOseek system.

More Summaries:
Novigenix, BioLizard, AI